Y. S. Wagh, B. M. Bhanage / Tetrahedron Letters 53 (2012) 6500–6503
6503
5, 2453–2455; (e) Evano, G.; Blanchard, N.; Toumi, M. Chem. Rev. 2008, 108,
3054–3131; (f) Rao, H.; Fu, H.; Jiang, Y.; Zhao, Y. Angew. Chem., Int. Ed. 2009, 48,
1114–1116.
removed under reduced pressure. The reaction mixture was analyzed using gas
chromatography (Perkin Elmer, Clarus 400) equipped with a flame ionization
detector (FID) and capillary column. The crude product was purified by column
chromatography (silica gel, 100–200 mesh; petroleum ether/ethyl acetate,
90:10) to afford pure products. All the prepared compounds were confirmed by
comparing with their authentic samples and were characterized by GC–MS
(Shimadzu QP 2010), 1H NMR (Varian 500 MHz).
N-Methyl-N-phenylbenzothiazol-2-amine (3, Table 3, entry 1): GC–MS (EI,
70 eV): m/z (%) = 240 (100), 239 (89), 106 (40), 77 (23).
N-Methyl-N-phenylbenzoxazol-2-amine (5a, Table 3, entry 2): GC–MS (EI,
70 eV): m/z (%) = 224 (100), 223 (39), 106 (41), 77 (30).
N,1-Dimethyl-N-phenyl-1H-benzoimidazol-2-amine (7, Table 3, entry 3): GC–MS
(EI, 70 eV): m/z (%) = 237 (100), 236 (70), 91 (15), 77 (22).
N,4,5-Trimethyl-N-phenylthiazol-2-amine (9, Table 3, entry 4): GC–MS (EI,
70 eV): m/z (%) = 218 (100), 217 (47), 77 (24), 51 (12).
2-Morpholinobenzoxazole (5b, Table 3, entry 5): GC–MS (EI, 70 eV): m/z
(%) = 204 (79), 147 (100), 119 (29). 1H NMR (500 MHz, CDCl3, 25 °C): d = 7.37
(d, J = 7.0 Hz, 1 H), 7.26 (d, 1 H, J = 6.5 Hz), 7.18 (m, 1 H), 7.04 (m, 1 H), 3.82 (m,
4 H), 3.7 (m, 4 H) ppm.
2-(Piperidin-1-yl)benzoxazole (5c, Table 3, entry 6): GC–MS (EI, 70 eV): m/z
(%) = 216 (100), 187 (23), 161 (29), 148 (50).
2-(Pyrrolidin-1-yl)benzoxazole (5d, Table 3, entry 7): GC–MS (EI, 70 eV): m/z
(%) = 188 (100), 160 (58), 146 (15), 133 (92). 1H NMR (500 MHz, CDCl3, 25 °C):
d = 7.36 (d, J = 7.5 Hz, 1 H), 7.25 (d, J = 8 Hz, 1 H), 7.15 (t, J = 7.5 Hz, 1 H), 7.00 (t,
J = 8 Hz, 1 H), 3.65 (t, J = 6 Hz, 4 H), 2.05 (t, J = 6 Hz, 4 H) ppm.
2-(4-Methylpiperazin-1-yl)benzoxazole (5e, Table 3, entry 8): GC–MS (EI, 70 eV):
m/z (%) = 217 (38), 160 (25), 147 (95), 70 (100).
1-(4-(Benzoxazol-2-yl)piperazin-1-yl)ethanone (5f, Table 3, entry 9): GC–MS (EI,
70 eV): m/z (%) = 245 (52), 160 (58), 147 (100), 43 (40). 1H NMR (500 MHz,
CDCl3, 25 °C): d = 7.37 (d, J = 7.5 Hz, 1 H), 7.27 (d, J = 7.5 Hz, 1 H), 7.2 (t,
J = 7.0 Hz, 1 H), 7.1 (t, J = 7.0 Hz, 1 H), 3.8–3.6 (m, 8 H), 2.16 (s, 3 H) ppm.
2-(3,4-Dihydroisoquinolin-2(1H)-yl)benzoxazole (5g, Table 3, entry 10): GC–MS
(EI, 70 eV): m/z (%) = 250 (51), 134 (10), 117 (100), 104 (30).
4. (a) Kakiuchi, F.; Kochi, T. Synthesis 2008, 3013–3039; (b) Dyker, G. Angew.
Chem., Int. Ed. 1999, 38, 1698–1712; (c) Alberico, D.; Scott, M. E.; Lautens, M.
Chem. Rev. 2007, 107, 174–238.
5. (a) Mori, A.; Sugie, A. Bull. Chem. Soc. Jpn. 2008, 81, 548–561; (b) Zificsak, C. A.;
Hlasta, D. J. Tetrahedron 2004, 60, 8991–9016; (c) Satoh, T.; Miura, M. Chem.
Lett. 2007, 36, 200–205; (d) Seregin, I. V.; Gevorgan, V. Chem. Soc. Rev. 2007, 36,
1173–1193.
6. (a) Yasuo, S.; Megumi, Y.; Satoshi, Y.; Tomoko, S.; Midori, I.; Tetsutaro, N.;
Kokichi, S.; Fukio, K. J. Med. Chem. 1998, 41, 3015–3021; (b) Yoshida, S.;
Shiokawa, S.; Kawano, K.-I.; Ito, T.; Murakami, H.; Suzuki, H.; Yasuo, S. J. Med.
Chem. 2005, 48, 7075–7079; (c) Gao, M.; Wang, M.; Hutchins, G. D.; Zheng, Q.-
H. Eur. J. Med. Chem. 2008, 43, 1570–1574; (d) Sato, Y.; Imai, M.; Amano, K.;
Iwamatsu, K.; Konno, F.; Kurata, Y.; Sakakibara, S.; Hachisu, M.; Izumi, M.;
Matsuki, N.; Saito, H. Biol. Pharm. Bull. 1997, 20, 752–755; (e) Verderame, M. J.
Med. Chem. 1972, 15, 693–694; (f) Liu, K. G.; Lo, J. R.; Comery, T. A.; Zhang, G.
M.; Zhang, J. Y.; Kowal, D. M.; Smith, D. L.; Di, L.; Kerns, E. H.; Schechter, L. E.;
Robichaud, A. J. Bioorg. Med. Chem. Lett. 2009, 19, 1115–1117.
7. Armstrong, A.; Collins, J. C. Angew. Chem., Int. Ed. 2010, 49, 2282–2285. and
references therein.
8. (a) Kawano, T.; Hirano, K.; Satoh, T.; Miura, M. J. Am. Chem. Soc. 2010, 132,
6900–6901; (b) Cho, S. H.; Kim, J. Y.; Lee, S. Y.; Chang, S. Angew. Chem., Int. Ed.
2009, 48, 9127–9130; (c) Kim, J. Y.; Cho, S. H.; Joseph, J.; Chang, S. Angew. Chem.,
Int. Ed. 2010, 49, 9899–9903; (d) Wang, J.; Hou, J.-T.; Wen, J.; Zhang, J.; Yu, X.-Q.
Chem. Commun. 2011, 47, 3652–3654; (e) Li, Y.; Xie, Y.; Zhang, R.; Jin, K.; Wang,
X. Duan., C J. Org. Chem. 2011, 76, 5444–5449.
9. (a) Joseph, J.; Kim, Y. J.; Chang, S. Chem. Eur. J. 2011, 17, 8294–8298; (b) Froehr,
T.; Sindlinger, C. P.; Kloeckner, U.; Finkbeiner, P.; Nachtsheim, B. J. J. Org. Lett.
2011, 13, 3754–3757; (c) Lamani, M.; Prabhu, K. R. J. Org. Chem. 2011, 76, 7938–
7944; (d) Wagh, Y. S.; Sawant, D. N.; Bhanage, B. M. Tetrahedron Lett. 2012, 53,
3482–3485.
10. Monguchi, D.; Fujiwara, T.; Furukawa, H.; Mori, A. Org. Lett. 2009, 11, 1607–
1610.
N,N-Dibutylbenzoxazol-2-amine (5h, Table 3, entry 11): GC–MS (EI, 70 eV): m/z
(%) = 246 (30), 173 (21), 161 (46), 147 (100).
11. General experimental procedure:
N-Benzyl-N-methylbenzoxazol-2-amine (5i, Table 3, entry 12): GC–MS (EI,
70 eV): m/z (%) = 238 (66), 222 (41), 147 (46), 91 (100).
6-Methyl-2-morpholinobenzoxazole (5j, Table 3, entry 13): GC–MS (EI, 70 eV):
m/z (%) = 218 (97), 161 (100), 94 (12), 77 (13).
6-Methyl-2-(piperidin-1-yl)benzoxazole (5k, Table 3, entry 14): GC–MS (EI,
70 eV): m/z (%) = 216 (100), 187 (23), 161 (29), 147 (31).
In a 25 mL two necked round bottom flask, azole (1 mmol), amine (2.0 mmol),
Cu(acac)2 (52.6 mg, 20 mol %), and 5 mL xylene were added. The above mixture
was kept under reflux condition and then molecular oxygen was bubbled into
the reaction mixture till the completion of reaction. The progress of reaction
was monitored using gas chromatography. After completion of the reaction,
the reaction mixture was filtered through celite bed. The organic solvent was